PFE · News · 20261104N
Revenue Performance and Mix
PFIZER INC · 2026-11-04 · Importance 52 · Surprise 56 · In source text
Pfizer reported Q3 2026 revenue of $16.6 billion, while non-COVID products grew 7% operationally as lower COVID-19 product revenue offset growth. Launched and acquired products generated $3.8 billion, up 32% operationally, with Padcev contributing $255 million of growth, Nurtec $135 million, and Lorbrena $114 million. COVID-19 products and the Prevnar family declined, while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena increased.
Key facts
- Pfizer reported Q3 2026 revenue of $16.6 billion, ahead of expectations. source
- Pfizer's annual dividend yield was 5.64%, with a quarterly dividend of $0.43 per share ($1.72 annually). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Pfizer reported Q3 2026 revenue of $16.6 billion, ahead of expectations. |